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Activation of guanylate cyclase-C (GC-C) expressed predominantly on intestinal epithelial
cells by guanylin, uroguanylin or the closely related GC-C agonist peptide, linaclotide,
stimulates generation, and release of cyclic guanosine-3′,5′-monophosphate (cGMP).
Evidence that the visceral analgesic effects of linaclotide are mediated by a novel,
GC-C-dependent peripheral sensory mechanism was ﬁrst demonstrated in animal models
of visceral pain. Subsequent studies with uroguanylin or linaclotide have conﬁrmed the
activation of a GC-C/cGMP pathway leading to increased submucosal cGMP mediated by
cGMP efﬂux pumps, which modulates intestinal nociceptor function resulting in peripheral
analgesia.These effects can be reproduced by the addition of exogenous cGMPand support
a role for GC-C/cGMP signaling in the regulation of visceral sensation, a physiological
function that has not previously been linked to the GC-C/cGMP pathway. Notably, targeting
the GC-C/cGMP pathway for treatment of gastrointestinal pain and abdominal sensory
symptoms has now been validated in the clinic. In 2012, linaclotide was approved in the
United States and European Union for the treatment of adult patients with irritable bowel
syndrome with constipation.
Keywords: abdominal pain, colonic nociceptor, cyclic guanosine monophosphate, guanylate cyclase-C, irritable
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INTRODUCTION
Guanylate cyclase-C (GC-C) is a type I transmembrane recep-
tor with intrinsic guanylate cyclase activity, belonging to a larger
family of enzymes comprising both soluble and receptor guany-
late cyclases that respond to a diverse range of signals by catalyzing
the conversion of guanosine triphosphate to cyclic guanosine-3′,5′
monophosphate (cGMP; Lucas et al., 2000; Vaandrager, 2002).
This receptor is expressed predominantly on the apical surface
of intestinal epithelial cells (IEC), and its important role in the
regulation of intestinal electrolyte and ﬂuid homeostasis is ﬁrmly
established (Schulz et al., 1990; Carrithers et al., 1996; Castro
et al., 2013; Silos-Santiago et al., 2013). The endogenous hormones
guanylin and uroguanylin, cognate ligands of GC-C, are expressed
in a distinct but overlapping regional pattern in enteroendocrine
cells along the longitudinal axis of the gastrointestinal (GI) tract
and released into the intestinal lumen (Currie et al., 1992; Kita
et al., 1994; Perkins et al., 1997; Qian et al., 2000; Silos-Santiago
et al., 2013). Activation of GC-C by either guanylin or uroguanylin
results in cGMP accumulation in IEC. Cyclic GMP is the sole sec-
ondmessenger generated byGC-Cand is known to regulate several
canonical intracellular signaling pathways mediated primarily
through direct interaction with three groups of target proteins:
cGMP-dependent protein kinases, cyclic nucleotide-gated ion
channels, and cGMP-regulated phosphodiesterases (Pfeifer et al.,
1996; Schlossman et al., 2005). Cyclic GMP regulation of intestinal
electrolyte and ﬂuid homeostasis is dependent on protein kinase
II (PKG-II) phosphorylation and activation of the cystic ﬁbro-
sis transmembrane conductance regulator (CFTR) ion channel,
stimulating transepithelial secretion of chloride and bicarbon-
ate ions and concomitant inhibition of sodium absorption by
the sodium/hydrogen exchanger 3 (NHE3), resulting in the net
efﬂux of ions and water into the lumen (Forte, 1999; Vaan-
drager, 2002; Sindic and Schlatter, 2006). Studies in GC-C null
(Gucy2c−/−) mice have conﬁrmed the central role of GC-C in the
control of electrolyte and ﬂuid homeostasis (Mann et al., 1997;
Schulz et al., 1997).
Our understanding of cellular processes regulated by activation
of the GC-C/cGMP pathway has markedly evolved over the past
two decades. Importantly, this knowledge has guided the develop-
ment of novel therapeutic paradigms targeting the GC-C/cGMP
pathway that have successfully translated into the clinic.
LINACLOTIDE IS A POTENT AND SELECTIVE GUANYLATE
CYCLASE-C AGONIST
Linaclotide, a synthetic 14-amino acid peptide composed of natu-
rally occurring amino acids (N-CCEYCCNPACTGCY-C; molec-
ular weight: 1524.2 Dalton), is a potent and selective agonist
of GC-C. This orally administered, minimally absorbed peptide
(≤0.1% in all non-clinical species) is a member of the guanylin
family of cGMP-regulating peptides that includes the natural hor-
mones guanylin and uroguanylin (Bryant et al., 2010; Busby et al.,
2010). Linaclotide is stabilized by three intramolecular disulﬁde
bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13), locking this peptide
into a single conformation similar in structure to guanylin and
uroguanylin,with the distinct difference that the biologically active
conformation (A-isoform) of these peptides contains only two
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disulﬁde bonds (Skelton et al., 1994; Marx et al., 1998; Busby et al.,
2010). Linaclotide exhibited high-afﬁnity and pH-independent
binding to GC-C on human colon carcinoma T84 cells and con-
comitantly stimulated a signiﬁcant and concentration-dependent
accumulation of intracellular cGMP, with greater potency than
guanylin or uroguanylin. In standard rodent models of GI func-
tion, orally administered linaclotide elicited signiﬁcant in vivo
pharmacological effects, stimulating ﬂuid secretion and acceler-
ating transit (Bryant et al., 2010; Busby et al., 2010). The lack
of such effects in Gucy2c−/−mice further conﬁrmed GC-C as
the molecular target of linaclotide and supported an underlying
mechanism linking the effects of linaclotide in these models to
local activation of GC-C in the intestine. The single pharmacolog-
ically active metabolite of linaclotide, MM-419447 (Des-Tyr14)
mirrors the effects of linaclotide in vitro and in vivo, pro-
viding evidence that this active metabolite contributes to the
pharmacology associated with oral administration of linaclotide
(Busby et al., 2013).
The potent pharmacological effects of linaclotide in non-
clinical models provided the rationale for development of this
peptide as a novel therapeutic for the treatment of functional GI
disorders associated with constipation, such as chronic idiopathic
constipation (CIC), and irritable bowel syndrome with consti-
pation (IBS-C). However, no reports had previously linked local
activation of the intestinal GC-C pathway to the regulation of
abdominal pain.
LINACLOTIDE ACTIVATION OF GUANYLATE CYCLASE-C
ELICITS ANALGESIC EFFECTS IN VISCERAL PAIN MODELS
Abdominal pain or discomfort (associated with a change in bowel
function) is a deﬁning symptom of the diagnostic criteria for
IBS and is hypothesized to originate from hypersensitivity of the
colon to mechanical stimuli (Drossman, 2006; Tack et al., 2006;
Videlock and Chang, 2007). In clinical studies, IBS patients have
shown lowered colorectal pain thresholds and increased sensory
ratings, further consistent with persistent enhanced perception
and responsiveness to visceral stimuli (= visceral hyperalgesia;
Mertz et al., 1995; Bouin et al., 2002).
Antinociceptive effects of an orally administered GC-C ago-
nist, linaclotide, were ﬁrst demonstrated by Eutamene et al.
(2010), using rodent models of visceral hypersensitivity asso-
ciated with inﬂammation produced by trinitrobenzene sulfonic
acid (TNBS) or stress models (following acute water avoidance or
partial restraint) that induce this condition. In these models, vis-
ceral pain is measured using colorectal balloon distension. This
well-characterized method evokes contractions of the abdom-
inal musculature (visceromotor response) to graded distension
pressures. It differs from measurements of visceral sensitivity in
humans, which is primarily based on conscious perception of con-
trolled colon distension. Orally administered linaclotide elicited
signiﬁcant analgesic effects during colonic distension in all models
tested,without affecting basal sensitivity. Notably, the speciﬁcity of
linaclotide-mediated analgesic effects was mechanistically linked
to the activation of intestinal GC-C, conﬁrmed in studies that
assessed the effects of linaclotide on TNBS-induced colonic hyper-
sensitivity inGucy2c wild-type andGucy2c−/− mice. In these stud-
ies, linaclotide reversed colonic hypersensitivity only in Gucy2c
wild-type, but not Gucy2c−/− mice. The analgesic effects of lina-
clotide were also reproduced by the endogenous GC-C ligand,
uroguanylin, a ﬁndingnot previously attributed to the endogenous
hormones. The analgesic effects of linaclotide and uroguanylin in
thesemodels were not associatedwith changes in colonic pressure-
volume relationships, further suggesting that the antinociceptive
effects are linked speciﬁcally to GC-C activation and are not asso-
ciated with altered colonic compliance (Eutamene et al., 2010;
Silos-Santiago et al., 2013). These ﬁndings raised the intriguing
question of whether activation of an intestinal GC-C pathway
had emerged as a novel physiological pathway regulating visceral
pain.
LINACLOTIDE INDUCES PERIPHERAL VISCERAL ANALGESIA
BY ACTIVATION OF A GUANYLATE
CYCLASE-C/EXTRACELLULAR cGMP PATHWAY
Hallmarks of IBS include allodynia (persistent response to nor-
mally non-noxious stimuli) and hyperalgesia (persistent enhanced
perception and responsiveness to noxious stimuli) to mechanical
stimuli within the intestine, mediated by chronic changes in affer-
ent pathways (sensitization). High-threshold colonic nociceptive
sensory afferents (mesenteric, serosal afferents) that only respond
at sufﬁciently high levels to mechanical stimulation are predomi-
nantly found in the splanchnic nerve pathway,while low-threshold
stretch receptors [muscular/mucosal (M/M), muscular afferents]
are predominantly found in the pelvic pathway (Hughes et al.,
2009; Feng and Gebhart, 2011; Blackshaw and Brierley, 2013).
In amousemodel of chronic post-inﬂammatory visceral hyper-
sensitivity (CVH) in which colonic mechanical hyperalgesia and
allodynia are evident long after resolutionof TNBS-induced colitis,
linaclotide, and uroguanylin reversed chronic mechanical hyper-
sensitivity in CVH colonic high-threshold splanchnic serosal noci-
ceptors, and also inhibited mechanical hypersensitivity of healthy
nociceptors. Inhibition of CVH colonic nociceptors by either pep-
tide was greater than their inhibition of control nociceptors from
healthy animals, and linaclotide-induced inhibition was more
potent than that produced by uroguanylin. Importantly, in vitro
inhibition of colonic nociceptors correlated with in vivo ﬁndings
in which linaclotide decreased the processing of noxious colorec-
tal distension stimuli in the thoracolumbar spinal cord indicated
by a lower number of activated dorsal horn (DH) neurons within
the thoracolumbar spinal cord, speciﬁcally the superﬁcial lamina
of the DH, recognized as the major termination zone for nocicep-
tive afferents (Castro et al., 2013). Further evidence supporting a
mechanism in which linaclotide inhibition of colonic nociceptors
is dependent on local activation of GC-C in IEC rather than direct
effects on colonic nociceptors was derived from expression studies
using in situ hybridization in whole adult mouse, colonic seg-
ments, and spinal cord and dorsal root ganglion (DRG) sections,
and studies assessing linaclotide inhibition of colonic nocicep-
tors in Gucy2c−/− mice. While abundant GC-C expression was
found in the intestine, no expression was detected in key sensory
structures, such as DRG and spinal cord neurons. Furthermore,
whilemechanosensory responses of colonicnociceptors at baseline
were similar in control and Gucy2−/− mice, linaclotide-induced
inhibition was completely lost in Gucy2c−/− mice. This was fur-
ther corroborated by ﬁndings that prior removal of the mucosa,
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the source of GC-C, in healthy and CVH states signiﬁcantly
attenuated linaclotide inhibition of colonic nociceptors (Castro
et al., 2013). Finally, electric ﬁeld stimulation-induced contrac-
tions of colonic tissues were not affected by linaclotide, which
conﬁrmed that antinociceptive effects of linaclotide were not
linked to altered smooth muscle cell contractility, consistent with
the absence of GC-C expression on colonic smooth muscle cells
(Castro et al., 2013).
While these ﬁndings indicate that the analgesic effects of lina-
clotide are mediated entirely by peripheral expression of GC-C on
the apical surface of IEC, a direct inhibitory effect of linaclotide
on colonic nociceptors was further considered unlikely because of
minimal absorption of this peptide, and the location of peripheral
endings of colonic nociceptors in the submucosa. This provoked
studies that investigated the potential role of cGMP, the com-
mon primary downstream effector of linaclotide and uroguanylin,
in altered intestinal nociceptor function and peripheral analge-
sia. The involvement of an intracellular GC-C/cGMP pathway
in the regulation of intestinal ﬂuid and electrolyte homeostasis
is ﬁrmly established; however, the effects of extracellular cGMP
transported out of IEC following local GC-C activation have
remained elusive. Precedence that extracellular cGMP is involved
in the modulation of neuronal activity was obtained from stud-
ies that showed direct inhibitory effects of extracellular cGMP on
CNS neurons, resulting in reduced excitability and inhibition of
neurotransmitter release (Linden et al., 1995; Poupoloupou and
Nowak, 1998; Cervetto et al., 2010). When assessed in rat mod-
els of colonic hypersensitivity, orally administered cGMP elicited
signiﬁcant analgesic effects, in a dose-dependent manner, repro-
ducing the effects of linaclotide and uroguanylin in these models
(Silos-Santiago et al., 2013). There is now compelling evidence
supporting a model in which the potent analgesic effects of cGMP
in vivo are mediated by a pathway linking extracellular cGMP,
secreted from IEC into the submucosa following activation of the
GC-C/cGMP pathway by linaclotide or uroguanylin, to altered
function of colonic nociceptors resulting in peripheral analgesia.
In vitro exposure of human intestinal Caco-2 cells to linaclotide or
uroguanylin stimulated extracellular transport of cGMP into the
apical and basolateral spaces, which was inhibited by the cGMP
efﬂux pump inhibitor probenecid in a concentration-dependent
manner (Castro et al., 2013; Silos-Santiago et al., 2013). This pro-
vided evidence implicating energy-dependent transport of cGMP
by the cGMP efﬂux pumps multidrug-resistance protein (MRP) 4
and 5 (Sager, 2004). While cGMP-binding phosphodiesterases are
generally recognized as themajor eliminationpathway for intracel-
lular cGMP, MRP4/5-mediated extracellular transport of cGMP is
consistentwith their function as overﬂowpumps, decreasing intra-
cellular cGMP levels under conditions when cGMP production is
strongly induced and importantly, providing extracellular cGMP
forparacrine actions (Ritter et al., 2005; Zimmermannet al., 2005).
Further evidence supporting a role of extracellular cGMP in the
regulation of colonic afferent activity was obtained from ex vivo
Ussing chamber assays, in which exposure of rat colonic tis-
sue (luminal side) to uroguanylin stimulated secretion of cGMP
into the submucosal space (Silos-Santiago et al., 2013). Moreover,
in a rat model of TNBS-induced colonic afferent sensitization,
exogenous cGMP signiﬁcantly decreased pelvic afferent ﬁring rates
in response to colonic distension, and in CVH mice colonic noci-
ceptors were signiﬁcantly inhibited by application of exogenous
cGMP to the mucosal epithelium, to a greater extent than those
from healthy mice (Castro et al., 2013; Silos-Santiago et al., 2013).
While cGMP dose levels required for inhibition of colonic noci-
ceptors exceeded those for linaclotide and uroguanylin, facilitating
access of cGMP to colonic nociceptors by removal of the mucosa
signiﬁcantly increased its potency, conﬁrming the barrier function
of the epithelium for luminal cGMP to diffuse across the mucosa
(Castro et al., 2013). Furthermore, direct application of cGMP
to mouse colorectal receptive endings signiﬁcantly decreased the
response of control pelvic muscular and M/M afferents to cir-
cumferential stretch, and sensitized responses of muscular and
M/M afferents to stretch were reversed (Feng et al., 2013). Simi-
lar to ﬁndings with linaclotide and uroguanylin, antinociceptive
effects of extracellular cGMP were not associated with altered
smooth muscle contractility (Castro et al., 2013; Silos-Santiago
et al., 2013).
In conclusion, accumulating evidence now strongly supports
a direct peripherally acting analgesic mechanism that, following
activation of a GC-C/extracellular cGMP pathway by selective
GC-C agonists, mediates inhibition of colonic nociception and
decreases visceral pain (Figure 1). This mechanism suggests that
the regulation of colonic sensation may have evolved as an effect
of GC-C agonism by the endogenous hormones guanylin and
uroguanylin in IEC (Castro et al., 2013; Silos-Santiago et al., 2013).
LINACLOTIDE DECREASES ABDOMINAL PAIN AND
DISCOMFORT IN PATIENTS WITH IRRITABLE BOWEL
SYNDROME WITH CONSTIPATION
Results from two pivotal phase 3 clinical trials with linaclotide in
adult patients with IBS-C have validated the approach of ther-
apeutically targeting the GC-C/cGMP pathway for treatment of
abdominal pain in this disorder (Chey et al., 2012; Rao et al.,
2012). The efﬁcacy and safety of linaclotide were assessed in a
26 week, double-blind, parallel-group, placebo-controlled, ran-
domized trial, and a 12 week, double-blind, parallel-group,
placebo-controlled, randomized trial, with a 4 week randomized
withdrawal period. In both trials, four prespeciﬁed primary end-
points were evaluated, based on the FDA primary endpoint for
IBS-C [responder: improvement ≥30% from baseline in average
daily worst abdominal pain score and increase by ≥1 complete
spontaneous bowelmovement (CSBM) frombaseline (sameweek)
for at least 50% of weeks assessed], and three other primary end-
points, based on improvements in abdominal pain and CSBM for
9/12 weeks. Notably, a 30% reduction in the pain score has pre-
viously been shown of clinical importance in IBS patients and in
patients reporting pain relief in general (Farrar et al., 2001; Spiegel
et al., 2009).
In the 26 week trial, 804 IBS-C patients randomized (1:1) to
linaclotide or placebo, received oral linaclotide (290 μg, once
daily) during the 26 week treatment period (primary and sec-
ondary efﬁcacy assessments were evaluated over the ﬁrst 12 weeks
of treatment; Chey et al., 2012). For the rigorous, combined IBS-C
endpoint recommended in the recent Guidance for IBS Clinical
Trials (Food and Drug Administration, 2010), 33.7% of IBS-
C patients in the linaclotide group were endpoint responders,
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FIGURE 1 | Proposed mechanism of action of guanylate cyclase-C
(GC-C) agonists modulating visceral pain, mediated through
activation of the GC-C/cyclic guanosine-3′,5′-monophosphate (cGMP)
pathway. (1) Linaclotide binds and activates GC-C, expressed at the
apical surface of intestinal epithelial cells. (2) Activation of GC-C results
in hydrolysis of guanosine triphosphate (GTP) and production of cGMP
inside intestinal epithelial cells. (3) Intracellular cGMP is actively
transported out of intestinal epithelial cells by efﬂux pumps into the
submucosa. (4) Extracellular cGMP is proposed to inhibit colonic
nociceptors. Adapted from Silos-Santiago et al. (2013); the ﬁgure has
been reproduced with permission of the International Association for the
Study of Pain® (IASP).
comparedwith 13.9% in the placebo group (P < 0.0001). The FDA
pain responder criterion was met by 48.9% of linaclotide-treated
patients, compared to 34.5% in the placebo group (P < 0.0001)
and similarly, 49.1% of linaclotide-treated patients met the
abdominal pain endpoint for at least 13/26 weeks, compared to
the placebo group (P < 0.0001). Furthermore, improvement in
abdominal pain compared toplacebo,was signiﬁcant starting from
the ﬁrst week of therapy and continuing throughout the 26 week
treatment period.
In the 12 week randomized trial, followed by a 4 week random-
ized withdrawal period, 800 patients (1:1, linaclotide or placebo)
received oral linaclotide (290 μg, once daily) during the 12 week
treatment period (Rao et al., 2012). Patients who had completed
all 12 weeks of the double-blind treatment period were eligi-
ble to enter the double-blind 4 week randomized withdrawal
period, in which patients initially randomized to linaclotide were
re-randomized (1:1) to oral linaclotide (290 μg, once daily) or
placebo, and patients previously randomized to placebo were
assigned to receive oral linaclotide (290 μg) once a day. The com-
bined FDA-recommended IBS-C responder endpoint was met by
33.6%, compared to 21% in the placebo group (P < 0.0001), and
similarly a larger number of linaclotide-treated patients (50.1%)
reported a reduction of ≥30% in abdominal pain, compared
to the placebo group (37.5%; P = 0.0003). As in the 26 week
clinical trial with linaclotide, improvement in abdominal pain
was recorded within the ﬁrst week of therapy and sustained
throughout the treatment period. During the 4 week random-
ized withdrawal period, patients on linaclotide had continued
relief of abdominal pain, while patients re-randomized to placebo
showed a gradual worsening of abdominal pain symptoms to the
level experienced by patients receiving placebo during the treat-
ment period, however, without worsening of symptoms relative to
baseline.
Finally, results from several pooled post hoc analyses of these
two phase 3 trials further conﬁrmed the efﬁcacy of linaclotide
treatment on symptoms of abdominal pain and discomfort in
patients with IBS-C (Johnston et al., 2013). Importantly, it was
shown in a post hoc longitudinal responder analysis using the FDA
responder criterion that at week 3, more than 50% of linaclotide-
treated patients reported >30% reduction in abdominal pain,
and that this analgesic effect increased to greater than 60% of
linaclotide-treated patients at week 7 and was sustained at approx-
imately 70% of linaclotide-treated patients for the duration of the
26 week study (Castro et al., 2013).
Based on results from these two phase 3 pivotal trials, lina-
clotide received FDA approval in 2012 as a ﬁrst-in-class drug for
the treatment of adult patients with IBS-C, and by the European
Medicines Agency for the symptomatic treatment of moderate to
severe IBS-C in adult patients. Linaclotide was also approved in
the US for the treatment of CIC (2012) and in Canada for the
treatment of both IBS-C and CIC (2013). Today, linaclotide is in
worldwide development for the treatment of IBS-C.
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SUMMARY AND PERSPECTIVE
This review offers a newperspective and understanding of endoge-
nous mechanisms involved in the regulation of visceral pain. The
intestinal GC-C/extracellular cGMP pathway is emerging as a
novel pathway that regulates peripheral analgesia via inhibition of
primary colonic afferents, which results in decreased visceral pain.
Findings from both non-clinical models and clinical studies have
conﬁrmed that the analgesic effects of linaclotide are mediated
by a distinct pain-regulating pathway that operates independently
from improvements in bowel function. In order to maximize the
beneﬁts of these novel ﬁndings for patients work is ongoing to
fully elucidate the underlying mechanisms of this pathway, such
as the identiﬁcation and characterization of the molecular tar-
get(s) on colonic afferents and secondly, to more broadly assess
the signiﬁcant therapeutic potential of targeting the GC-C/cGMP
pathway in GI disorders associated with visceral pain. The efﬁ-
cacy of linaclotide on abdominal pain demonstrated in the phase
3 IBS-C clinical trials translates the targeting of the GC-C/cGMP
pain pathway into the clinic. This pathway continues to emerge as
a novel therapeutic target for GI dysfunction with the potential for
broader utility in treating visceral pain.
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